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Abstract: I n t r o d u c t i o n :  Oxidative stress with an excessive free radical production and a reduction 
in the activity of protective antioxidants is considered as one of the mechanisms responsible for gluten 
toxicity. However, its role in celiac disease (CD) is unclear.
O b j e c t i v e s: Evaluation of plasma nonenzymatic antioxidant capacity in patients with CD (both 
untreated patients and those receiving gluten-free diet [GFD]) by measuring the ferric reducing ability of 
plasma (FRAP) as well as assessing selected plasma antioxidants.
P a t i e n t s  a n d  m e t h o d s: Th e study included 169 adult patients: 48 patients with untreated active 
CD, 72 patients with CD on a GFD, and 49 healthy controls. In each group, we measured the serum levels 
of selected antioxidants (uric acid, bilirubin, albumin, and vitamin E) and used the FRAP assay to assess 
the total antioxidant capacity (TAC) of plasma. In each patient, serological and histopathological activity 
of CD was also evaluated.
R e s u l t s: Th ere were no signifi cant diff erences in the TAC of plasma measured with the FRAP assay 
between the study groups. Patients with CD had higher uric acid levels compared with controls (p <0.001), 
while bilirubin levels were lower in patients with active disease than in controls (p <0.05). Serum vitamin 
E levels were lower in all patients with CD compared with controls (p <0.01). 
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C o n c l u s i o n s: Th e FRAP assay is not the method of choice for assessing the TAC of plasma in 
patients with CD. Owing to high serum uric acid levels, the FRAP assay results in these patients may be 
overestimated despite the reduced levels of other plasma antioxidants.
Key words: celiac disease, oxidative stress, FRAP assay, total antioxidant capacity, uric acid.
Introduction
Celiac disease (CD) is a chronic infl ammatory disease of the small intestine that 
occurs in genetically predisposed individuals due to intolerance of proline- and 
glutamine-rich protein contained in wheat, barley, and rye. Activation of the innate 
and adaptive immune systems results in histological changes to the small intestine 
including intraepithelial lymphocytosis, crypt hyperplasia, and villous atrophy. Th is 
leads to impaired nutrient absorption from the gastrointestinal tract [1]. Activation 
of the immune system by gluten peptides is commonly believed to be an important 
mechanism involved in the pathogenesis and progression of CD [2]. However, recent 
studies have pointed to another possible pathogenetic mechanism of CD, namely, the 
direct cytotoxic eff ect of gluten on enterocytes. Th is eff ect is associated with oxidative 
stress, a phenomenon related to excessive free radical production and reduced activity 
of protective antioxidants [3]. As a result of reduced antioxidant protection, the 
infl amed intestinal mucosa may become more vulnerable to oxidative damage and 
its regenerative capacity may become impaired, which in turn compromises mucosal 
integrity. Moreover, the impairment of intestinal permeability enhances the toxic 
eff ects of environmental factors. 
In physiological conditions, the damaging eff ects of free radicals are counteracted 
by the antioxidant system, which includes antioxidant enzymes (glutathione 
peroxidase, glutathione reductase, superoxide dismutase, and catalase), nonenzymatic 
antioxidants (glutathione, albumin, bilirubin, ceruloplasmin, and uric acid), as well as 
nutrient antioxidants (carotenoids; vitamins A, C, and E) [4].
There is an increasing body of evidence suggesting a relationship between 
oxidative stress and CD. Studies have revealed a reduced activity of peroxidase and 
glutathione reductase, as well as decreased glutathione levels, in the small intestine 
of patients with CD, while an increased activity of copper- and zinc-containing 
superoxide dismutase has been shown in patients with active CD [5, 6]. Reduced 
glutathione peroxidase activity may be partially explained by glutathione defi ciency 
due to chronic inflammation of the small intestine [7]. Moreover, patients with 
CD show reduced absorption of vitamins, including vitamin E [8]. Finally, these 
patients have a reduced expression of the antioxidant and anti-infl ammatory enzymes 
paraoxonase 1 and 3 in the small intestine [9].
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Th e assessment of the severity of oxidative stress, including the evaluation of 
antioxidant capacity, in patients with CD may have therapeutic implications. It should 
be hypothesized that oral antioxidant supplementation may reduce the toxic eff ects 
of peptides contained in gluten on enterocytes and help alleviate histological lesions, 
thus exerting benefi cial eff ects on the course of the disease. Th erefore, antioxidant 
supplementation, in addition to a lifelong gluten-free diet [GFD], may prove to be 
an eff ective additional treatment in patients with CD, especially those who do not 
fully adhere to GFD. Th e latter patients are likely those with the most severe oxidative 
stress, thus antioxidant supplementation may additionally lower the risk of possible 
complications from CD.
Th ere is currently no standard method of choice for assessing antioxidant activity. 
Th e available techniques include all assays for individual antioxidants as well as the 
assessment of the so called total antioxidant capacity (TAC), which is the measure of 
the antioxidant capabilities of all individual compounds in a studied sample. 
Th e components of the plasma/serum antioxidant defense system include uric acid 
(35–65%), plasma protein (10–50%), vitamin C (~14%), and vitamin E (~7%) [10]. 
According to other authors, the plasma components contributing to its TAC include 
the -SH groups (52.9%), uric acid (33.1%), vitamin C (4.7%), total bilirubin (2.4%), 
vitamin E (1.7%), and others (5.2%) [11]. Considering the involvement of numerous 
plasma components in antioxidant defense, as well as a possible variation in their 
distribution, it is generally agreed that the assessment of the TAC is more valuable 
than that of individual antioxidants in pathological conditions that are strongly 
related to oxidative stress [11]. Th e evaluation of TAC may provide information on 
the individual susceptibility to oxidative stress.
Th ere are 2 ways for antioxidants to scavenge free radicals: through hydrogen 
atom transfer or single atom transfer. Consequently, there are 2 types of TAC assay: 
1) hydrogen atom transfer-based assays (e.g. oxygen radical absorbance capacity 
[ORAC], total reactive antioxidant potential [TRAP]), which measure the antioxidant 
capacity to scavenge free radicals by donating hydrogen, and 2) single atom transfer-
based assays (e.g. ferric reducing ability of plasma [FRAP], cupric reducing antioxidant 
capacity [CUPRAC]), which measure the antioxidant capacity to e– transfer and free 
radical or metal ion reduction. TAC assays are widely used as they are easy and quick 
to perform [12]; they are based on assessing the free radical scavenging activity and 
reducing potential of antioxidants [12, 13]. Th ey were originally developed for assessing 
the TAC of foods and nutrients. However, biological fl uids contain not only nutrient 
antioxidants, but also different types of endogenous antioxidant enzymes, dietary 
antioxidants, and even oxidizing products [14, 15]. Th erefore, the use of diff erent assays 
for measuring the TAC of biological samples is being investigated in various diseases. 
Th ere have been few studies assessing the TAC with the above assays in patients 
with CD. Th us, the aim of this study was to assess plasma nonenzymatic antioxidants 
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in patients with CD, both untreated patients and those on a GFD, by using the FRAP 
assay. To our knowledge, this is the fi rst such study in this patient group. Additionally, 
we measured the levels of selected individual components of the plasma antioxidant 
system: uric acid, albumin, bilirubin, and vitamin E.
Patients and Methods
Th e study included 169 outpatients of the Clinic and Department of Gastroenterology 
and Hepatology of the University Hospital in Kraków, Poland. Th e study group was 
divided into 3 subgroups. Th e fi rst subgroup included 48 untreated patients with 
active CD (39 women and 9 men; mean age, 35.1 ± 11.07), both newly diagnosed 
individuals and those nonadherent to GFD, who were positive for celiac antibodies. 
Th e second subgroup included 72 patients with CD (60 women and 12 men; mean age, 
40.74 ± 14.84) who remained on a GFD for at least 2 years (mean disease duration, 
10.63 ± 8.3 years). Th e third subgroup included 49 healthy controls (41  women and 
8 men; mean age, 40.13 ± 12.83 years) with functional gastrointestinal disorders, 
without endoscopic abnormalities of the upper gastrointestinal tract, without 
duodenal abnormalities on a histological biopsy, and with negative test results for anti-
endomysial antibodies (anti-EmAs) or anti-transglutaminase antibodies (anti-TGAs). 
CD was diagnosed on the basis of a clinical picture, positive test results for anti-
EmAs or anti-TGAs, as well as typical histological fi ndings on duodenal biopsy. All 
patients underwent an endoscopic examination of the upper gastrointestinal tract, and 
at least 4 duodenal biopsy specimens were obtained for a histopathological study. Th e 
Marsh classifi cation was used to assess the degree of damage to intestinal mucosa [16].
On the day of the endoscopic examination, blood samples were obtained from the 
antecubital vein to assess the levels of anti-EmAs and anti-TGAs, C-reactive protein 
(CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (AP), γ-glutamyltransferase (GGT), total protein, albumin, bilirubin, uric 
acid, and vitamin E. Anti-TGA titers were measured using a commercial enzyme-
linked immunosorbent assay (ELISA; Aesku Diagnostics GmbH, Germany), and the 
results were expressed as units (U)/ml of serum. Th e results exceeding 15 U/mL were 
considered positive. Anti-EmA titers were measured using an immunofl uorescent 
assay, and the results exceeding 1:10 were considered positive. Th e exclusion criteria 
were as follows: diabetes, inflammatory bowel diseases, active infection, history 
of cancer, chronic hepatic and hepatobiliary diseases, chronic renal failure, alcohol 
abuse, smoking, chronic use of nonsteroidal anti-inflammatory drugs, as well as 
the use of antioxidant supplements, oral contraceptives, immunostimulants, and 
immunosuppressants.
All patients provided written informed consent to participate in the study, and 
the study protocol was approved by the Ethics Committee of Jagiellonian University 
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Medical College in Kraków (KBET/174/B/2013). The study was conducted in 
accordance with the principles laid down by the Declaration of Helsinki.
Blood tests
Blood samples were drawn in the morning in the fasting state. On the same day, the 
levels of CRP, ALT, AST, AP, GGT, total protein, albumin, bilirubin, and uric acid 
were measured. For vitamin E level measurement, the blood was centrifuged at 1000 
g for 15 minutes at a temperature of 4°C. Th e obtained serum samples were stored at 
a temperature of –80°C until further analysis.
Measurement of vitamin E levels
Vitamin E levels were measured using the commercial General Vitamin E Elisa Kit 
E0922Ge, according to the manufacturer’s instructions (Wuhan EIAab Science). To 
assess optic density at a wavelength of 450 nm, a microplate spectrophotometer was 
used (Stat Fax 2100 Awareness Technology Inc., Palm City, USA).
FRAP assay
Th e FRAP assay was conducted according to the method by Benzie and Strain [17], 
with slight modifi cation, using 48-well plates, an automated reader (Synergy-2, 
BioTek, USA), and syringe rapid dispensers [18]. Each well was fi lled with 0.4 ml of 
acetate buff er (pH, 3.6), followed by 50 μl of plasma. Th e plate was conditioned at 
a temperature of 37°C for 2 minutes, and then 0.2 ml of reactive mixture (1:1 [vol./
vol.] 20 mM ferric (III) chloride [FeCl3·6H2O, POCh] and 10 mM tripyridyltriazine 
[Sigma] in 40 mM HCl [POCh]) was shaken for 30 seconds. Absorbance at 
a wavelength of 593 nm was measured with kinetic mode for 15 minutes. Th e method 
was calibrated by the use of ferrous sulphate pentahydrate FeSO4·5H2O (POCh) 
standard solution with a concentration range of 0–1.5 mM. Th e reducing ability of 
the sample was expressed in ferrous ion equivalents in plasma (μmol Fe2+/L). Each 
sample was run in triplicate.
Statistical analysis
Descriptive statistics was used for the analysis of all studied parameters. Th e normal 
distribution of variables was assessed using the Kolmogorov–Smirnov test. Th e study 
groups were compared using the analysis of variance with the post hoc Tukey test for 
normally distributed variables and homogeneous variances or the Kruskal-Wallis test 
with the post hoc Dunn test for all the remaining variables. A p value of less than 
18 Agnieszka Piątek-Guziewicz, Paweł Zagrodzki, et al.
0.05 was considered statistically signifi cant. Th e statistical analysis was performed 
using the commercial soft ware packages: STATISTICA PL v.10 (StatSoft , Tulsa, USA) 
and GraphPad Prism v.3.02 (GraphPad Soft ware, San Diego, USA).
Results
Blood test results in controls and patients with celiac disease
Th e laboratory test results are presented in Table 1. Th e mean CRP levels were higher 
in patients with treated and untreated CD, as compared with controls (p <0.01 and 
p <0.001, respectively). Th e mean AST and ALT levels were signifi cantly higher 
in patients with CD than in controls, without signifi cant diff erences between the 
subgroups of treated and untreated patients with CD.
Table 1. Laboratory test results in the study subgroups: controls, patients with untreated celiac disease, 
and patients with treated celiac disease. 
Controls (n = 49)
Patients with CD (n = 120)
Treated CD (n = 72) Untreated CD (n = 48)
Mean ± SD Median Mean ± SD Median Mean ± SD Median
Albumin (g/L) 42.2 ± 3.9 41.0 44.1 ± 3.0c 44.0 43.1 ± 4.3 43.5
AP (U/L) 52.0 ± 20.2 46.0 61.5 ± 25.4c 55.0 64.4 ± 26.3c 52.0
ALT (U/L) 16.7 ± 6.4 16.0 22.3 ± 12.9e 20.0 26.8 ± 21.9c 20.0
AST (U/L) 17.1 ± 4.2 17.0 22.2 ± 6.2d 22.0 26.9 ± 16.3d 22.0
Bilirubin (μmol/L) 9.7 ± 3.7 9.2 9.1 ± 4.1 8.2 8.5 ± 5.4e 7.7
CRP 0.7 ±0.6 0.5 1.8 ± 4.2c 0.5 2.7 ± 7.1d 0.8
GGT (U/L) 20.4 ± 11.5 16.0 17.2 ± 15.3 14.0 36.6 ± 101.6 10.5e
Total protein (g/L) 74.1 ± 5.7 76.0 71.2 ± 5.0e 72.0 72.3 ± 7.5 73.0
Uric acid (μmol/L) 186.1 ± 37.2 188.0 254.9 ± 46.5d 247.0 260.3 ± 56.2d 240.0
Vitamin E (μmol/L) 48.3 ± 21.0 50.1 38.2 ± 36.2c 28.6 42.0 ± 36.7c 31.1
ap <0.001 versus treated CD; bp <0.05 versus treated CD; cp <0.01 versus controls; dp <0.001 versus controls; 
ep <0.05 versus controls
Abbreviations: ALT —  alanine aminotrasferase; AP —  alkaline phosphatase; AST —  aspartate aminotrasnferase; 
CD — celiac disease; GGT — γ-glutamyltransferase
Hypertransaminasemia was observed in 10 patients (20.8%) with untreated active 
CD and in 9 patients (12.5%) with treated CD, but not in controls. Th e mean AP 
levels were lower in controls than in patients with CD (p <0.05). Th e mean GGT levels 
were higher in patients with active CD than in controls (p <0.05).
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Th e mean albumin levels did not diff er between the subgroups of patients with 
CD, but were lower in controls compared with patients on a GFD (p <0.01). Th e 
mean total protein levels were lower in patients with CD on a GFD than in controls 
(p <0.05). Serum uric acid levels were elevated only in patients with CD: in 4 patients 
(8.3%) with active CD and in 4 patients (5.5%) on a GFD. Uric acid levels were 
higher in patients with CD irrespective of the treatment status, as compared with 
controls (p <0.001), while bilirubin levels were lower in patients with active CD than 
in controls (p <0.05).
Serum vitamin E levels 
Serum vitamin E levels were lower in untreated and treated patients with CD, as 
compared with controls (42.0 ± 36.7 μmol/L vs 48.3 ± 21.0 μmol/L and 38.2 ± 36.2 
μmol/L vs 48.3 ± 21.0 μmol/L, respectively, p <0.01). 
Vitamin E defi ciency, defi ned as the level below 16.2 μmol/L, was observed for 
more than 15.4% of patients with CD and 9.5% of controls. Optimal vitamin E levels 
(>30 μmol/L), which is required for protection against cardiovascular disease and 
cancer, were shown for less than 46% of patients with CD and more than 83% of 
controls.
Total antioxidant capacity expressed as the ferric reducing ability of plasma
Th ere were no signifi cant diff erences between the groups in terms of the TAC 
measured with the FRAP assay (Table 2).
Table 2. Total antioxidant capacity measured with the FRAP assay in controls, patients with untreated 
celiac disease, and patients with treated celiac disease. 
Controls (n = 49)
Patients with CD (n = 120)
Treated CD (n = 72) Untreated CD (n = 48)
Mean ± SD Median Mean ± SD Median Mean ± SD Median
FRAP (μmol Fe2+/L) 787.1 ± 157.9 746.1 824.6 ± 153.1 802.3 824.0 ± 181.7 767.1
Abbreviations: FRAP — ferric reducing ability of plasma; others — see Table 1
Anti-endomysial and anti-transglutaminase antibody titers and intestinal 
mucosal damage
Patients in the control group tested negative for anti-EmA and anti-TGA titers 
(Table  3). Signifi cantly higher antibody titers were revealed for untreated patients 
with CD, while they were signifi cantly lower in patients treated with a GFD compared 
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with those with untreated disease. Th e degree of damage to intestinal mucosa was the 
lowest in the control group, while it was higher in patients on a GFD and the highest 
in patients with active CD. Th e diff erences between the groups were signifi cant 
(Table 3).
Table 3. Clinical characteristics of the study groups: celiac disease antibody titers and the degree of 
intestinal mucosal damage on histological examination.
Controls
(n = 49)
Treated CD
(n = 72)
Untreated CD
(n = 48)
Antibody titer 
0 49 (100%) 70 (97.2%) 2 (4.2%)
1 0 2 (2.8%) 13 (27.1%)
2 0 0 15 (31.3%)
3 0 0 18 (37.5%)
Antibody titer 
mean ± SD 0 0.02 ± 0.2 2.02 ± 0.9a,b
median 0 0 2
Degree of intestinal mucosal damage1
Normal mucosa — 0 47 (95.9%) 30 (41.7%) 3 (6.2%)
Marsh 1 — 1 2 (4.1%) 26 (36.1%) 10 (20.8%)
Marsh 2 — 2 0 0 0
Marsh 3a — 3 0 6 (8.3%) 9 (18.8%)
Marsh 3b — 4 0 9 (12.5%) 14 (29.2%)
Marsh 3c — 5 0 1 (1.4%) 12(25%)
Degree of intestinal mucosal damage1
mean ± SD 0.04 ± 0.2 1.2 ± 1.5 3.2 ± 1.6
median 0.0 1.0a 4.0a,b
Data are expressed as number (percentage) of patients or as mean ± SD and median. 
Antibody titer:0, negative; 1, low (anti-TGA <3 × ULN; anti-EmA [+]); 2, high (3 × ULN < anti-TGA <10 × ULN; 
anti-EmA [++]); 3, very high (anti-TGA >10 × ULN; anti-EmA [+++])
1classifi ed according to the Marsh classifi cation; each stage was scored from0 (normal mucosa) to 5 (total villous 
atrophy)
ap <0.001 vs control; bp <0.001 vs treated CD
Abbreviations: anti-EmA —  anti-endomysial antibodies; anti-TGA —  anti-transglutaminase antibodies; ULN 
— upper limit of normal; others — see Table 1
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Discussion
Th e pathogenesis of CD has not been fully elucidated so far. Infl ammation and 
oxidative stress associated with higher levels of reactive oxygen species and reduced 
antioxidant defense seem to be involved in the molecular mechanism of the disease. 
Literature data provide an increasing body of evidence for a signifi cant association 
between oxidative stress and CD, and particularly for reduced antioxidant activity in 
patients with CD, independent of age.
In diseases that are significantly associated with oxidative stress, the TAC is 
usually measured to assess the individual susceptibility to oxidative stress, which may 
help elucidate the pathogenesis of the disease and implement appropriate treatment. 
However, there have been few studies assessing the TAC in patients with CD. Ferreti 
et al. [19] showed that the TAC measured with the ORAC assay is significantly 
lower in patients with CD, irrespective of diet, as compared with controls. Moreover, 
patients on a GFD showed a signifi cantly higher TAC in comparison with untreated 
individuals, although the levels did not reach those observed in controls. Th e results 
suggest that GFD can only partially improve intestinal mucosal function. 
Ersin Sayar et al. [20] also showed lower TAC, assessed using the method 
described by Erel [11], in pediatric patients with CD in comparison with healthy 
controls. Moreover, the TAC was signifi cantly higher in patients with CD aft er starting 
treatment with a GFD, as compared with the baseline values.
To our knowledge, this study is the fi rst to use the FRAP assay to assess the TAC 
in patients with CD. Th is method was previously used by Moslemnezhad et al. [21] to 
assess the TAC in patients with Alzheimer disease. Th e authors showed signifi cantly 
lower results of the FRAP assay in patients than in controls.
Surprisingly, we did not observe diff erences in the FRAP assay results between 
patients with CD and the control group. Th is fi nding can be explained by the diff erent 
composition of individual antioxidants in the FRAP assay in comparison with the 
other assays for TAC assessment. Th is is in agreement with the results of Lee et al. 
[22], who compared 4 diff erent assays for assessing the TAC of plasma (including the 
2,2’-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid [ABTS] radical scavenging assay, 
1,1-diphenyl-2-picrylhydrazyl [DPPH] radical scavenging assay, FRAP, and ORAC), in 
relation to the 8-isoprostane concentration in urine. Th ey showed a higher correlation 
of ABTS results with the 8-isoprostane concentration than in the case of the other 
assays. Th ey also showed a positive correlation between the ABTS and FRAP assay 
results, which is in line with previous observations [23–25]. Th is phenomenon can be 
partially explained by a signifi cant antioxidant contribution of uric acid and ascorbic 
acid to the TAC measured with the 2 above assays [15, 24, 26]. Not all tests measure 
the same antioxidants. In humans, ascorbic acid, α-tocopherol, and, most importantly, 
uric acid are the main components of the TAC measured by the FRAP assay, while 
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thiols and albumin —  of that measured by the CURPAC assay. Th e FRAP method 
assumes that if an antioxidant can reduce the ferric ion Fe3+, then it is also capable 
of reducing the ferric ion Fe2+. Uric and ascorbic acids are typical compounds that 
show both these activities; therefore, the results of the FRAP assay can be signifi cantly 
associated with their plasma concentrations [27].
Studies conducted to date have shown reduced vitamin E and ascorbic acid levels 
in patients with CD [8, 28], which can be explained by impaired absorption of nutrient 
antioxidants due to intestinal mucosal damage. Th ese observations are corroborated 
by the results of our study. Unlike Hozyasz et al. [29], who reported signifi cantly 
lower serum levels of α-tocopherol in untreated patients with CD in comparison with 
those on a GFD, our current and previous studies [30] revealed signifi cantly lower 
serum vitamin E levels in both subgroups of patients with CD, irrespective of the diet. 
Importantly, the GFD did not result in a signifi cant increase in vitamin E levels. 
In our previous study [30], we evaluated uric acid as a nonenzymatic antioxidant 
in the serum of adult patients with CD. Both in the previous and in the current 
studies, we showed signifi cantly higher uric acid levels in patients with CD than in 
controls despite the lack of metabolic disorders that could have otherwise account 
for this fi nding. Uric acid is considered a marker of oxidative stress, but also as a 
protective factor with antioxidant activity [31, 32]. It is one of the most important 
antioxidants in human biological fl uids, as it is responsible for neutralizing more than 
50% of free radicals in blood [33].
Elevation in uric acid levels is a physiological response to oxidative stress [34]. 
It is possible that hyperuricemia is a compensatory or protective mechanism for the 
prevention or correction of oxidative damage. Our results seem to suggest that the 
elevated uric acid levels in patients with CD in comparison with controls are caused 
by oxidative stress and that uric acid may function here as an antioxidant. Its role in 
diseases related to oxidative stress has not been fully elucidated, but experimental and 
clinical studies have confi rmed its antioxidant activity in vivo [33]. It is eff ective in 
scavenging free radicals but also in stabilizing ascorbic acid levels in serum [35].
Th e signifi cant contribution of uric acid to the TAC measured by the FRAP assay, 
as well as the signifi cant increase in uric acid levels in both subgroups of patients with 
CD in our study, may explain why we did not observe signifi cant diff erences in the 
FRAP assay results between patients with CD and controls despite the fact that other 
active antioxidants in plasma were lower than in controls.
An interesting finding was the fact that the mean AST and ALT levels were 
signifi cantly higher in both celiac subgroups, as compared with controls. Th is is in 
line with the results of a study by Castillo et al. [36], who showed that liver enzyme 
levels were higher at diagnosis in 40% to 50% of adult and pediatric patients with 
CD. Th e risk of nonalcoholic fatty liver disease is higher in patients with CD than in 
the general population not only in the fi rst year but also in the 15 years of diagnosis 
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[37]. One of the explanations of hypertransaminasemia in patients with CD is altered 
intestinal permeability, as it is responsible for the passage of intestinal toxins to the 
liver through the portal venous system. Th is may produce an infl ammatory reaction 
in the liver due to oxidative stress. However, further studies are needed to explain 
the pathogenesis of hepatitis related to gluten sensitivity as well as the involvement of 
oxidative imbalance in this condition.
Unlike transaminase levels, the bilirubin level in active CD was signifi cantly lower 
in patients with active CD, as compared with controls. Like α-tocopherol, bilirubin 
is a well-known antioxidant [38]. It has a similar capability of reducing oxidized 
phospholipids as antioxidant vitamins [39]. Signifi cantly lower bilirubin levels were 
reported in patients with severe asthma in an Australian study [40], which suggested 
the modulatory effect of antioxidant vitamins and bilirubin on inflammation in 
asthma. Th is fi nding is in line with our results, suggesting altered bilirubin levels in 
response to oxidative stress.
In summary, the lack of signifi cant diff erences between the study groups in terms 
of the FRAP assay results, as observed in our study, does not translate into the lack of 
reduced TAC in patients with CD. On one hand, it may suggest a signifi cant role of 
uric acid as one of the main plasma antioxidants in CD, but on the other hand, it may 
also suggest signifi cantly reduced activity of the antioxidants that are not measured by 
the FRAP assay.
Considering the above conclusion, it seems justifi ed to question the appropriateness 
of the term “total antioxidant capacity” [41], as this parameter never actually refl ects 
the TAC of the body. Plasma or serum TAC does not refl ect the antioxidant capacity 
of the whole blood, as it does not include antioxidant enzymes in blood cells and 
vascular walls; therefore, “nonenzymatic antioxidant capacity” seems to be a more 
appropriate term to describe the TAC [42]. Our results also indicate that in patients 
with CD it is enzymatic antioxidants that play the major role in oxidative imbalance. 
Th e reduced activity of these antioxidants in this population has been reported before 
[5, 6, 9].
In conclusion, the study of antioxidant capacity in patients with CD should 
primarily include the assessment of the activity of enzymatic antioxidants in addition 
to plasma nonenzymatic antioxidants. Moreover, the assessment of antioxidant 
capacity in patients with CD should not be limited to the use of the FRAP assay, 
as this may result in false results. Studies comparing the diff erent assays for TAC 
measurement in patients with CD are needed to select the method of choice that 
would best refl ect susceptibility to oxidative stress in these patients. Assays for the 
assessment of plasma TAC may be particularly useful in clinical practice, because 
they are easy to perform, quick, and cost-eff ective. Th ey may prove valuable as an 
initial diagnostic test or as a tool for therapy monitoring in patients with CD.
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